Meanwhile, immunotherapy CR ranged from 1%–7% in PD-L1 negative patients and 6%–16% for PD-L1 positive patients.13Given the poor CR rate of systemic therapy, there is room for improvement for treatment of advanced renal cancer. Here, CD274 is linked to renal carcinoma.